Expert Insights

Finding a high-affinity antibody that binds to your target is only the first step. Not every antibody has what it takes to become a licensed medicine.

Waving goodbye to antibody engineering and moving your lead candidates into transient protein expression is a big milestone in therapeutic antibody development. Wise developers budget a few weeks into their timelines to invest in a small-scale pilot project before scaling up.

With their high specificity, efficacy and safety profiles, it’s no wonder that antibodies have become the biggest selling drugs in recent years.

The most effective medicines in the world are of limited value if they can’t be produced in bulk, and at a reasonable cost. Therapeutic antibodies take years to develop. Without good oversight, each stage of development risks operating in a vacuum...